Loading...
•
Dec 31, 2024
Global Medical REIT Q4 2024 Earnings Report
Global Medical REIT reported its financial results for the fourth quarter and full year ended December 31, 2024, highlighting increased rental revenue and strategic acquisitions, alongside a joint venture with Heitman.
Key Takeaways
Global Medical REIT experienced a 6.1% year-over-year increase in rental revenue for Q4 2024, reaching $35.0 million, primarily driven by recent acquisitions. Despite this, net income attributable to common stockholders was $1.4 million, or $0.02 per diluted share, impacted by one-time severance costs and an impairment charge. The company also announced a joint venture with Heitman and provided 2025 AFFO guidance.
Rental revenue for the fourth quarter of 2024 increased by 6.1% year-over-year to $35.0 million, driven by acquisitions.
Net income attributable to common stockholders for Q4 2024 was $1.4 million ($0.02 per diluted share), compared to a net loss of $0.8 million ($0.01 per diluted share) in the prior year period.
The company completed the acquisition of 10 properties from a 15-property portfolio for $49.5 million and entered into a joint venture with Heitman, selling two assets for $35.2 million.
FFO attributable to common stockholders and noncontrolling interest was $11.1 million ($0.15 per share and unit), and AFFO was $15.8 million ($0.22 per share and unit) for Q4 2024.
Revenue by Segment
Forward Guidance
Global Medical REIT is introducing full year 2025 AFFO per share and unit guidance of $0.89 to $0.93, based on assumptions including no additional acquisitions or dispositions beyond announced activity and no further equity or debt issuances other than normal course Revolver borrowing/repayments.
Positive Outlook
- Guidance range of $0.89 to $0.93 AFFO per share and unit for full year 2025.
- Expects to complete the acquisition of the remaining two properties from the five-property portfolio during Q2 2025.
- New 15-year triple-net lease with CHRISTUS Health for the Beaumont, Texas facility, with rent commencing in Q2 2025.
- Joint venture with Heitman is expected to provide additional opportunities to acquire assets and earn ancillary fee income.
- The company's disciplined acquisition approach for quality healthcare real estate is expected to continue.
Challenges Ahead
- Guidance assumes no additional acquisitions or dispositions beyond what has been completed or announced.
- Guidance assumes no additional equity or debt issuances other than normal course Revolver borrowing/repayments.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...